Insulin 2019 – Global Intelligence Center Database with Coverage from 2012 to 2023 –

Intelligence Center 2012-2023”
report has been added to’s

The Insulin Intelligence Center is a global intelligence
database platform, which provides data, covering five regions with
in-depth analysis across 25 countries with a five-year forecast,
including value, volume sales, price, and price per capita expenditure.

The intelligence center enhances your understanding of the human insulin
drugs market. The market is also assessed considering the economic
factors, such as Type-1 diabetic population level, Type-2 diabetic
population level, and obesity, which will provide you with actionable
business insights.

Market Scope

  • The human insulin drugs market data, volume, and value analytics with
    growth trends (2012-2023).
  • Branded and biosimilar drugs data for 2012-2023.
  • Market indicators – Diabetic population levels, diabetes disease
    prevalence, diabetic Type-1 population level, diabetic Type-2
    population level, and per capita expenditure.
  • The IC for human insulin drugs provides exhaustive coverage (countries
    covered account for more than 80% of the overall spending on
    diabetes), covering two categories, six segments, and tracking of over
    10,000 data points.


  • Branded Insulin Drugs
  • Biosimilar Insulin Drugs


  • Basal Insulin or Long-acting Insulin
  • Bolus Insulin or Fast-acting Insulin
  • Pre-mixed Insulin or Combination Insulin
  • Traditional Human Insulin
  • Traditional Human Insulin Biosimilars
  • Insulin Glargine Biosimilars

Market Overview

  • The global human insulin drugs market is expected to register a CAGR
    of 4.93% during the forecast period (2018-2023), and was valued at USD
    24 billion by 2018.
  • Diabetes is generally considered as a lifestyle-related disease. Over
    time, incidences of the disease have increased outrageously, with the
    increase in global population. Approximately, 100 million people
    around the world need insulin, including all the people suffering from
    Type-1 diabetes and between 10%-25% of people suffering from Type-2
  • Although insulin has been used in the treatment of diabetes for over
    90 years, globally, more than half of those who need insulin today
    still cannot afford and access it. People suffering from Type-1
    diabetes need insulin therapy, which focuses on managing blood sugar
    levels, along with insulin, diet, and lifestyle, in order to prevent

Insulin Drugs Under Development

  • Novo Nordisk is developing a first once-weekly long-acting insulin
    (LAI287), which is currently in phase 2. The insulin is indicated for
    both Type-1 and Type-2 diabetic population levels.
  • Eli Lilly is developing a long-acting insulin-Fc (LY3209590). “Basal
    insulin-Fc” is a large molecule comprised of engineered insulin fused
    to an Fc domain, designed to provide a long-acting basal profile.
    LY3209590 is being studied for the treatment of diabetes.

Oral Insulin’s Drugs will boost the market

  • Biocon is developing Insulin Tregopil, an oral prandial insulin
    tablet, for the treatment of Type-1 and Type-2 diabetes mellitus. The
    fast-acting oral insulin may improve post-prandial glucose control
    with reduced side effects and greater adherence, thus, holding the
    promise to transform Type-1 diabetes management.
  • Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company,
    focused on the development of oral drug delivery systems, is working
    to bring the first oral insulin product to market, thus, providing a
    more convenient, effective, and safer method for delivering insulin

Reasons to Purchase this Dashboard

  • More Granular: Covers more categories, segments, and information on
    brands at country- and global levels than the other market
    intelligence providers
  • Provides an outlook of the market with recent market and historical
    data and market forecast
  • Ease of Comparability: Analytics are based on the standardized
    definition across the world, in order to facilitate better
    comparability of market data
  • View the market in different ways among categories and geography to
    understand where the actual opportunity lies
  • Market segmentation, including quantitative research, incorporating
    the impact of economic and non-economic aspects
  • Regional- and country-level data integrating the demand and supply
    forces that are influencing the growth of the market
  • Market value (in USD million) and volume (in ml million) data for each
    segment and sub-segment
  • Understanding of the market, due to value and volume changes,
    intra-category competition
  • Dedicated analyst support for research queries and training
  • Continuous amendment of a yearly database with significant changes,
    updated based on scenarios

Countries Covered

  • United States
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Mexico
  • Brazil
  • Japan
  • South Korea
  • China
  • India
  • Australia
  • Vietnam
  • Malaysia
  • Indonesia
  • Philippines
  • Thailand
  • Saudi Arabia
  • Iran
  • Egypt
  • Oman
  • South Africa

Companies Mentioned

  • Eli Lilly
  • Novo Nordisk
  • Sanofi

List of Topics Covered

1. Introduction

1.1 Key Deliverables of the Study

1.2 Market Definition

2. Research Approach and Methodology

2.1 Introduction

2.2 Research Designs

2.3 Study Phases

2.3.1 Internal sources evaluation

2.3.2 Research Process

2.3.3 Modeling & triangulation

2.3.4 Data finalization

2.3.5 Expert Validation

3. Market Segmentation

3.1 By Drug

3.1.1 Insulin

3.2 Geography

3.2.1 North America

3.2.2 Europe

3.2.3 Latin America

3.2.4 Asia-Pacific

3.2.5 Middle East and Africa

4. Market Indicators

4.1 Type-1 Diabetes population (2012-2023)

4.2 Type-2 Diabetes population (2012-2023)

5. Company Share Analysis

For more information about this report visit

Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Endocrine
and Metabolic Disorders Drugs